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ABSTRACT
The article handles two related subjects. First, it’s the study of forced-acid/heat degradation of phenazopyridine HCl (PAP).
The reaction pathway was evidenced with different criteria. A three wavelengths-based reversed phase HPLC method with an
isocratic mobile phase system (acetonitrile:acetate buffer of pH 4, 1:1, v/v) was developed as a stability-indicating assay of particular application for simultaneous determination of PAP and its related degradation products/impurity. The analysis time was
less than 8 min at a flow rate of 1 mL min-1. The detection and quantification limits of degradation products/impurity were in the
ranges of 0.02-0.1 and 0.06-0.3 µg mL -1, respectively. The impurity profile of PAP in drug substance and tablets was investigated
and could be determined down to a level between 0.03% and 0.005%. The second subject deals with establishment of spectrofluorimetric method for quantification of phenol (PH) and 2,6-diaminopyridine (DAP), as degradant/impurity in PAP, at trace concentrations. The method is based on measurement of the native fluorescence in acidic ethanol solution (DAP) or in aqueous acidic
solution (PH). The method was applied to check the purity/stability of PAP in drug substance and in tablets dosage form.
Key words: phenazopyridine HCl, forced-acid/heat degradation, impurity, stability-indicating HPLC assay, spectrofluorimetry

INTRODUCTION
P h e n a z o p y r i d i n e HC l , PA P, 2 ,6 - D i a m i n o -3 (phenylazo) pyridine hydrochloride exerts an analgesic
effect on the mucosa of the urinary tract and is used to
provide symptomatic relief of pain in conditions such
as cystitis and urethritis. It is given in conjunction with
an antibacterial agent for the treatment of urinary tract
infections (1).
HPLC (2- 4) and spectrophotometry (5-7) have been
widely applied for the determination of PAP in combinations with each of sulfa drugs, nitrofurantoin, ampicillin
or nalidixic acid. Also, polarographic method has been
reported (8).
The USP 28(9) specifies spectrophotmetric and HPLC
methods for the analysis of PAP in bulk powder and
tablets dosage form, respectively. The pharmacopoeial
monograph describes an isocratic HPLC assay procedure
without limits specification for the related impurities.
Micellar electrokinetic chromatographic method (10)
has been reported for the analysis of PAP and its related
degradation products/impurity present in tablets form.
The method allowed to resolve and quantify three degradation products/impurity namely, 2,6-diaminopyridine,
2-amino-3-(phenylazo)-6-pyridinol and 3-(phenylazo)-2,6* Author for correspondence.
E-mail: suzymsabry@hotmail.com

pyridindiol at a level of 0.1%. However, the two structural
isomers, 2-amino-3-(phenylazo)-6-pyridinol and 6-amino3-(phenylazo)-2-pyridinol, could not be resolved by such a
method. Reference azo substances were used and no study
about the degradation reaction was carried out.
Recently, photochemistry of PAP was studied in
different reaction media including the drug adsorbed on
silica gel. This resulted in photochemical cyclo-dehydrogenation, reductive photo-degradation and rearrangement of the drug molecule (11).
The present work handles the subject of forced-acid/
heat degradation of PAP. The study is aimed to investigate the inherent stability of the drug and to develop a
validated stability indicating HPLC assay. The developed
HPLC/UV-detection method demonstrated that the acid
degraded PAP solution yields 6 peaks, from decomposition, with different retention times. Three degradation
azo/hydrazo-products were isolated and purified from
degraded PAP solution and the structure was elucidated
by mass spectrometry (MS), 1 H-NMR and 13 C-NMR
spectrometry, and elemental analysis. Phenol (PH) and
2,6-diaminopyridine (DAP) reference substances were
used to identify the other two products. The developed
HPLC method was capable of simultaneous determination
of PAP and its related degradation products/impurity.
Additionally, the work aims to quantify the related
impurities, PH and DAP (starting material in the synthet-
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ic pathway of PAP(12)) at trace concentrations, based on
measurement of the native fluorescence in acidic ethanol
solution (DAP) or in aqueous acidic solution (PH). Both
methods were applied to check the purity/stability of
PAP in drug substance and in tablets dosage form.

drazo pyridine-2-one, 6-PA-3-PH). The substances used
are those which isolated and purified from degraded PAP
solution.

MATERIALS AND METHODS

A mixture of PAP (500 mg dissolved in 10 mL of hot
water) and 2 M sulfuric acid solution (10 mL of hot solution) was incubated in a boiling water bath for 1hr. The
azo/hydrazo compounds were separated, as bulky orangered precipitate, after cooling the reaction mixture for 4hr.
The azo/hydrazo compounds were then filtered, washed
with 0.2 M sulfuric acid and dried. The dried azo/hydrazo mixture was added to 30 mL of chloroform, stirred for
2hr at room temperature, and then filtered. The extraction
with chloroform was repeated. The combined chloroform
extract was evaporated and the azo compound was purified by crystallization from ethanol/water. The other azo/
hydrazo compounds (dried) were treated with 15 mL of 0.2
M NaOH, 6-PA-3-PH was separated as yellow precipitate,
filtered and dried. The latter was reconstituted in 0.05 M
sulfuric acid, to form sulfate salt, filtered and dried, and
re-crystallized from dimethylformamide/0.05 M sulfuric
acid. The alkaline solution, remained after the separation
of 6-PA-3-PH, was re-acidified with 2 M sulfuric acid.
6OL-PAP was separated as dark red-brown precipitate.
The latter was filtered, dried and re-crystallized from
dimethylformamide/water.

I. Instrument
The HPLC system used was Perkin Elmer Series
200 (USA), equipped with a quaternary pump solvent
delivery system, auto-sampler and UV detector. The
column used was Spheri-5, RP-8 5 µ (220 × 4.6 mm ID,
Perkin Elmer, USA). Isocratic elution was carried out
using a mobile phase of acetonitrile and acetate buffer,
pH 4, (1:1, v/v). The injection volume was 50 µL. The
column temperature was maintained at 20-30°C. The
flow rate was set at 1.0 mL min-1 throughout the run.
Fluorescence spectra and measurements were taken
on a RF-1501 Shimadzu Spectrof luorometer, equipped
with 1-cm quartz cell and Xenon lamp. The slit width of
excitation/emission monochromators was set at 10 nm.
13
C-NMR spectra were recorded on JEOL a spectrometer (125 MHz, δ ppm) using TMS as an internal
standard and DMSO-d 6 as solvent. 1H-NMR spectra
were recorded on JEOL spectrometer (500 MHz, δ ppm)
using DMSO-d 6 as solvent.
Mass spectra were run on Finnigan Mass Spectrometer, model SSQ/7000 (70 eV, Thermo Electron Corporation).
The microanalyses were performed at the Micro-analytical Laboratory, National Research Center, Cairo, Egypt.
II. Chemicals
Analytical-grade chemicals and solvent were used
th roughout the work. Phenazopy r idine hyd rochlor ide was pu rchased f rom Heu man n Phar ma, Nü r nberg, Germany. 2,6-diaminopyridine and phenol were
pu rchased f rom Sigma Ald r ich, Ger many. Ur isept
tablets (labeled to contain 100 mg PAP per tablet) were
obtained Kahira Pharm. Co., Egypt. Britton Robinson
buffer was prepared as 40 mM each of acetic acid/boric
acid/o-phosphoric acid mixture with the required pH
adjusted with 0.2 M sodium hydroxide solution.
III. Preparation of Standard Solutions
Reference standard solutions of PAP, PH and DAP
were prepared in hot distilled water (500 µg mL -1 each)
and stored at 4°C. The solutions are stable at least for
two days. Standard solutions of azo/hydrazo compounds
(200 µg mL -1 each) were prepared in 50% ethanol/water
(3-(phenylazo)-2,6-pyridindiol, 2,6DOL-PAP) or 50%
dimethylformamide/water (2-amino-3-(phenylazo)-6pyridinol, 6OL-PAP, and 6-phenylamino-3-phenylhy-

IV. Degradation Reaction, Isolation and Purification of the
Azo/Hydrazo Species

V. Spectrofluorimetric Determination of 2,6-Diaminopyridine and Phenol
Suitable dilutions of the standard solutions of DAP
and PH to give final concentration ranges of 0.0004 to
0.006 and 0.01 to 0.15 µg mL -1, respectively, were made
with acidic ethanol (measurement of DAP) or 0.1 M
sulfuric acid (measurement of PH). The f luorescence
intensities were measured at the specified wavelengths
using solvent as blank.
VI. Preparation of Phenazopyridine HCl Tablets Assay
Solutions
A total of 20 Urisept tablets were weighed and finely
powdered. A portion of the powder, equivalent to 50 mg of
PAP, was accurately weighed and about 50 mL of hot distilled
water was added. PAP was dissolved using ultrasonic bath
and the mixture was filtered into a 100-mL volumetric flask
and diluted to volume with distilled water. Working solutions for HPLC analysis were prepared by dilution of the
PAP solution with the mobile phase. For fluorimetric purity
test, working test solutions (equivalent to 2.5 μg mL-1 PAP)
were prepared by suitable dilution with either acidic ethanol
(measurement of DAP) or 0.1 M sulfuric acid (measurement
of PH). The fluorescence intensities were measured at the
specified wavelengths using solvent as blank.
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RESULTS AND DISCUSSION
I. Forced-Acid/Heat Degradation Reaction
(I) Degradation Reaction Pathway
Referring to PAP molecule, the azo link associates
phenyl and DAP moieties. Stress acid/heat effects the
cleavage of the phenylazo moiety and/or favors the amino
group hydroxylation. The degradation reaction pathway
(Figure 1) showed six products, namely, 2,6DOL-PAP,
6OL-PAP, 6-PA-3-PH, PH, DAP and 3-hydroxy-2,6diaminopyridine (HDAP).
(II) Evidence of Degradation Reaction Pathway
In order to gain a bet ter understanding of this
acid-catalyzed degradation pathway of PAP, MS was
employed to identify and characterize the structure of
three species isolated from PAP degradation products.
The three species can be assigned as 6OL-PAP, isolated
as sulfate salt, (C11H10N4O)2 H 2SO 4, 6-PA-3-PH, isolated
as sulfate salt, C17 H14 N 4 O) 2 H 2 SO 4 and 2,6DOL-PAP
isolated as base C11 H 9 N 3 O 2 . The mass spectr um of

2-amino-3-(phenylazo)-6-pyridinol of molecular mass
of 214 is shown in Figure 2A with diagnostic fragment
ions m/z 214 (96.6%), m/z 137 (59.6%, loss of phenyl
moiety), m/z 109 (73.0%, loss of azo group), m/z 92
(29.2%, loss of OH) and m/z 77 (96.6%, phenyl or pyridine residue). The mass spectrum of 3-(phenylazo)-2,6pyridindiol of molecular mass of 215 is shown in Figure
2B with diagnostic fragment ions m/z 215 (94.3%), m/z
138 (39.3%, loss of phenyl moiety), m/z 110 (23.1%, loss
of azo group), m/z 93 (10.5%, loss of OH) and m/z 77
(100.0%, phenyl or pyridine residue). The mass spectrum of 6-phenylamino-3-phenylhydrazo pyridine-2-one
of molecular mass of 290 is shown in Figure 2C with key
fragment ions m/z 290 (39.8%), m/z 185 (32.8%, fragmentation of phenylhydrazo residue, M+1), m/z 107 (10.2%,
loss of phenyl), m/z 93 (25.9%, loss of phenylamino
moiety) and m/z 77 (94.8%, phenyl or pyridine residue).
A great deal of similarity of fragmentation patterns are
seen in these three mass spectra.
1
H-NMR of 6-PA-3-PH (DMSO-D6, δ ppm): 5.67 (d,
1H, J = 9.90 Hz, C5 -H pyridyl), 7.27 (t, 2H, J = 7.65 Hz,
C 4 -H C6 H5 NH + C 4 -H C6 H5 NNH), 7.40 (t, 4H, J = 7.65
Hz, C3,5 -H C6 H5 NH + C3,5 -H C6 H5 NNH), 7.69 (d, 4H, J
= 7.65 Hz, C2,6 -H C6 H5 NH + C2,6 -H C6 H5 NNH), 7.81 (d,

HO

N

NH2
N

N

6OL-PAP

H 2N

N

HO

NH2
N

N

H

N

OH

+

N

N

2,6DOL-PAP

Phenazopyridine

H
N

N

H
N

O

N

N

OH
N

NH

6-PA-3-PH
OH
H2N

N

NH2

H2N

N

NH2
OH

PH

Figure 1. Acid- degradation pathway of PAP.
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1H, J = 9.95 Hz, C 4 -H pyridyl), 11.01 (s, 2H, 2 NH).
13
C-NMR of 6-PA-3-PH (DMSO-D6, δ ppm): 106.63
(C 5 - pyridyl), 119.03 (C 2,6 - C6H5NH), 119.27 (C 2,6 C 6 H 5 N NH), 121.71 (C 4 - C 6 H 5 NH + C 4 - C 6 H 5 N NH),
128.58 (C 4 - pyridyl), 129.57 (C 3,5 - C 6 H 5 NH + C 3,5 C6 H5 NNH ), 150 (C1- C6 H5 NNH), 151.15 (C1- C6 H5 NH),
152.99 (C3,6 - pyridyl), 162.40 (C=O).
The interpretation of MS, 1H-NMR, 13C-NMR of the
isolated product, 6-PA-3-PH, refers to a quinoid-hydrazo
structure (Figure 1); however, in aqueous solutions, electron
delocalization with structural rearrangement to hydroxylazo form is another probable option as deduced from
voltammetric and fluorescence measurements (see below).
Elemental analysis of 6OL-PAP sulfate; C22H22N8SO6,
Mr 526. Calculated percentages: C 50.18%, H 4.21%.
Found percentages: C 49.73%, H 4.02%. Elemental
analysis of 2,6DOL-PAP; C11H9N3O2, Mr 215. Calculated
percentages: C 61.39%, H 4.22%. Found percentages: C
61.73%, H 4.09%.
It should be noted that the probability of the azo
species, 6OL-PAP mixing with its structural isomer,
2OL -PA P can not be judged by MS. Even though
6OL-PAP was eluted as a single peak in the HPLC chromatogram, there is no definite confirmation of the peak
purity, i.e. absence of the relevant isomer.
The voltammetric cathodic activity of PAP is attributed to the reduction of the electroactive azo bond at
the mercury electrode surface (13) . The voltammetric
peaks of PAP and the three azo/hydrazo species in Britton Robinson buffer of pH 5, are displayed in Figure 3;
all are turned around -250 to -350 mV, indicating the

3
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100

200

300
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Figure 3. Cathodic voltammograms of PAP (2 µg mL -1, 1),
6OL-PAP (3 µg mL -1, 2), 6PA-3-PH (3 µg mL -1, 3) and 2,6DOL-PAP
(4 µg mL-1, 4).

presence of the azo link in the separated three products,
especially in 6PA-3-PH (as referred above).
The yield of PH and DAP in degraded PAP mixture is
so small that they can not be isolated. The identity of PH
and DAP was confirmed through peak enrichment in the
spiking-in experiments with reference substances, HPLC
analysis of degraded PAP mixture. Further, fluorimetric
measurements of degraded PAP mixture indicated two
types of fluorophores with fluorescence emission in the
visible (λ ex/em = 325/390 nm, in acidic ethanol) and UV
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regions (λ ex/em = 270/299 nm, in aqueous acidic solution).
Such characteristic fluorescence emission spectra match
with those of the reference substances, DAP and PH.
The azo link quenches the f luorescence emission
from 2,6-diaminopyridine moiety in PAP molecule.
Accordingly, PAP shows no f luorescence. This fact
points three approaches. First, 6OL-PAP showed no
f luorescence. Second, 6PA-3-PH exhibited no f luorescence and this agrees with the probability of hydroxylazo structure form, in solution (Figure 1). Third, the
fluorescence of degraded PAP mixture is certainly due to
the cleavage of the azo link.
(III) Degradants Profile through HPLC Separation
Six degradation products were resolved by the
current HPLC method (Figure 4). Peaks 2, 3 and 4 refer
to three azo/hydrazo species. Peak 5 and 6 refer to PH
and DAP, respectively. Peak 7, at retention time of 2.5
min, is most probably due to 3-hydroxy-2,6-diaminopyridine (HDAP). However, no reference substance was
available for the identification.
II. HPLC Method
(I) Method Development
The products of acid-catalyzed degradation of PAP
comprise three categories: azo/hydrazo compounds, amino
pyridines and phenol. The only common share is the
polar function groups, OH or NH 2. They exhibit different

Response (mV)

5-

270 nm

2

4

1-

2-

4-

3-

360 nm

0

6

(II) Method Validation
1. System Suitability Parameters
System suitability parameters were measured to
verify the system performance. All important characteristics including peak resolution, theoretical plate number,
peak asymmetry and system precision were measured
and calculated by carrying out six replicate injections of
each standard solution onto the chromatographic system
(Table 1).
2. Linearity of Phenazopyridine HCl and Degradation
Products
Samples of six concentration levels were prepared
and injected twice for each level onto HPLC. The results
of linear regression analysis of the peak areas versus the
concentrations are shown in Table 1.

6-

7-

325 nm

UV-VIS spectral characteristics with significantly apart
maxima. Three wavelength-based chromatographic analyses were employed to enhance the analytical sensitivity.
The wavelengths, 360, 325 and 270 nm were chosen for
the quantification of azo/hydrazo compounds, DAP and
PH, respectively. Although the absorption maxima of
PAP and azo/hydrazo degradation compounds turn around
410 nm, but it is tedious to switch the light source during
chromatographic runs. The analytical response of PAP
and 2,6DOL-PAP and 6OL-PAP signals is slightly better
at 360 nm than at 270 nm. However, 6PA-3-PH signal
showed 3-fold enhancement at 360 nm, which is quite
important in the determination of impurity level.
Efficient separation of PAP and its related degradation products/impurity was achieved using RP-C8column. Binary mobile phase system of acetonitrile
and acetate buffer was tested to adequately resolve the
mixture. Both the buffer pH and the % organic modifier potentially affect the separation especially for the
azo/hydrazo compounds. Using acetate buffer with
pH 5 to 6.5 and methanol of 55~80%, the azo/hydrazo
compounds are only par tially resolved. Resolution
was substantially improved at pH 4 and 50% methanol.
Briefly, satisfactory chromatographic separation of seven
peaks was achieved in less than 8 min with mobile phase
flow rate of 1 mL min-1.

8

10

12

Time (min)

Figure 4. Chromatograms of the active substance, PAP (20 µg mL -1,
(1)) plus its degradation products, 6OL-PAP (2), 2,6DOL-PAP (3),
6PA-3-PH (4), PH (5), DAP (6), HDAP (7) in three successive runs
at 360, 270, and 325 nm.

3. Day to Day Variation/Robustness
Day to day variation was assessed; three different
samples of PAP near 20 µg mL -1 were prepared on three
days and injected each in triplicate. The mean %RSD
over three days was 1.6%. Analogous investigation
was carried out for other compounds and the results are
given in Table 1. The robustness is taken as a measure
of method capacity to remain unaffected by small, but
deliberate, variations in method parameters. The influence of small changes in mobile phase composition was
examined. A variation of ±0.1 pH unit of acetate buffer
has nearly nil effect while a change of ±5% methanol has
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Table 1. HPLC method validation results
PAP

6OL-PAP

2,6DOL-PAP

6PA-3-PH

PH

DAP

System suitability parameters
Retention time

5.66

Theoretical plates
Asymmetry
Resolution

4.72

4.33

3.86

3.36

3.16

3150

2360

9160

4000

8170

1120

3

2.3

1.4

1.8

1.3

1.5

2.4

1.4

2.2

2.2

7

2.6

a

0.2

0.2

0.1

0.1

0.2

0.3

a

0.05

0.06

0.04

0.08

0.06

0.06

0.5-200

0.5-200

0.2-200

0.25-250

0.6-300

0.1-100

a ± SD

-3293 ± 9540

3141 ± 2620

-19350 ± 21700

24204 ± 26600

-7625 ± 46940

11253 ± 21880

b ± SD

59440 ± 188

49959 ± 114

0.9999

0.9996

0.9999

0.9998

0.9996

0.9998

1.6

2.1

2.4

1.9

1.1

1.2

% Recoveryc

99.7

99.9

101

99.5

98.3

100.9

Accuracy (%Er)

-0.3

-0.1

+1

-0.5

-1.7

+0.9

Repeatability-tr

Repeatability-A
Validation

Concentration range (µg mL-1)
Regression data (n = 6)

r
Day-to-day precision
(% RSD)b

Precision (%RSD)

150070 ± 260

121900 ± 259

66556 ± 550

319589 ± 995

0.5

0.8

0.8

1.3

1.2

0.5

-1

0.1

0.1

0.03

0.04

0.1

0.02

-1

0.3

0.3

0.1

0.12

0.3

0.06

LOD (µg mL )
LOQ (µg mL )

a, Intercept; b, slope; r, correlation coefficient; Sa, standard deviation of intercept; Sb, standard deviation of slope.
a
%RSD calculated for six replicates.
b
Mean %RSD for three samples injected in triplicates up to three days.
c
Mean for four mixtures (of six components) prepared in ratios 1:1 and 2:1 PAP/degredant at two concentration levels.

a marked effect on the peak retention time and separation, especially on those of the azo/hydrazo-compounds.
4. Accuracy and Precision
The accuracy (% E r) and precision (%RSD) of the
developed HPLC method for simultaneous determination of PAP/degradants were investigated by analyzing
of standard mixtures prepared in ratios of 1:1 and 2:1,
respectively (Table 1).
5. Specificity
The following study was carried out to evaluate
the specificity of the chromatographic system. First,
standard solutions of PAP and of degradations products/
impurity were injected onto the chromatographic system
and the retention times were recorded (Table 1). The
specificity was proven by the absence of interference
with the peak of PAP or even mutual interference of the
six degradants. Second, a solution of placebo pharmaceutical preparations (adjuvant co-formulated in tablets,
lactose, starch, and magnesium stearate) was injected.
The chromatogram of such solution showed no peaks

throughout the run time of the HPLC method. Third,
the tablets assay solution was also injected (20 µg mL -1).
The chromatogram of such solution showed single peak
at 5.66 min due to PAP. Spiking of standard PAP to such
test solution resulted in the increase in area of the peak
at 5.66 min.
6. Limits of Detection and Quantification
Limits of detection (LOD) and quantification (LOQ)
were determined, at signal to noise ratio of 3:1 and 10:1,
respectively, for PAP and its degradation products/impurity. The detection and quantification limits were in the
ranges of 0.02-0.1 and 0.06-0.3 µg mL -1, respectively.
Details were given in Table 1.
7. Standard Solutions Stability
No degradation was detected after storage of standard solutions of PAP, PH and DAP at 4°C or room
temperature for 48 hr. The recoveries were within
98~101%. Solution of 2,6DOL-PAP (50% ethanol/water)
was stable up to 24 hr. Significant decomposition was
observed after 6PA-3-PH and 6OL-PAP (50% dimethyl-
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formamide/water) solutions were stored at room temperature for 24 hr.
(III) Applications
1. Levels of Degradation Products/impurity in Phenazopyridine HCl
The recovery was determined by spiking PAP reference substance with either PH, DAP, 6OL-PAP, 6PA-3-PH
or 2,6DOL-PAP solution at three levels. An accurately
weighed PAP reference substance (20 mg) was dissolved
in 5 mL of boiling distilled water in a 10-mL volumetric
flask. This solution was spiked with the examined impu-

rity solution and the volume was made up with water.
Two solutions were prepared at each level and injected
twice each. The average % recoveries were: from 99% to
101% for PH at a level down to 0.03%, from 97% to 101%
for DAP at a level down to 0.005%, from 98% to 100% for
2,6DOL-PAP at a level down to 0.01%, from 99% to 101%
for 6PA-3-PH at a level down to 0.0125%, and from 98%
to 102% for 6OL-PAP at a level down to 0.025%.
2. Analysis of Commercial Tablets
The HPLC method was applied to determine PAP in
two batches of commercial tablets. The method gave satisfactory precision and recovery data as shown in Table 2.

Table 2. Analysis of phenazopyridine hydrochloride in tablets and detection of its related impurities in tablets and drug substance
Target

HPLC method

Reference methoda

Spectrofluorimetry

b

Urisept tablets

Batch 1 (3 years-aged)
PAP %Found± SDc

99.5 ± 0.5
t = 0.13, F = 3.69d

99.5 ± 0.97

Level of impurities (%)
PH

0.06

ND

DAP

0.13

0.15

e

2,6DOL-PAP

D

6PA-3-PH

NDf

6OL-PAP

D

Batch 2 (6 months-aged)
PAP %Found± SDc

100.3 ± 0.6
t = 0.92, F = 1.17d

100.0 ± 0.59

Level of impurities (%)
PH

0.02

ND

DAP

0.05

0.06

2,6DOL-PAP

D

6PA-3-PH

ND

6OL-PAP

D

Phenazopyridine drug substance
Level of impurities (%)

a

PH

0.03

ND

DAP

0.01

ND

2,6DOL-PAP

ND

6PA-3-PH

ND

6OL-PAP

D

Ref. 9.
Urisept tablets are labeled to contain 100 mg PAP, manufactured by Kahira Pharmaceutical Co., Egypt.
c
Mean %Found±standard deviation of five determinations.
d
Tabulated t-value for p = 0.05 and f = 8 is 2.306, tabulated F-value for p = 0.05 and f1 = f 2 = 4 is 6.38,
e
Detected only.
f
Not detected.
b
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T he product s tested were con f i r med a s bei ng
compendial quality in term of the drug content using
USP HPLC (9) . The results obtained were compared
statistically by Student’s t- and variance ratio F- tests;
the calculated values did not exceed the theoretical one
demonstrating that the proposed methods are as accurate
and precise as the reference one.
3. Detection of Related Impurities in Phenazopyridine
HCl Drug Substance and Tablets

Relative fluorescence intensity

600
PH
DAP
400

200

Solutions of PAP drug substance and Urisept tablets
(two batches; one is three years aged and the other is
six months aged) were prepared at a concentration of
2000 µg mL -1 PAP, to detect any of the related impurities/degradants by HPLC assay. The results were listed in
Table 2. The three years-aged tablets sample showed relatively higher level of impurities, PH, DAP, 6OL-PAP and
2,6DOL-PAP. Anyhow the level of impurities was in the
acceptable range.
4. Analysis of Acid-catalyzed Degraded Phenazopyridine HCl Solution
Three standard PAP solutions (100 µg mL -1) were
subject ed to a cid- cat aly zed / heat deg r a d at ion a nd
analyzed by the proposed HPLC method. The investigation demonstrated that acid-catalyzed/heat degradation
of 100 µg mL -1 PAP resulted in formation of 0.7 ± 0.02
µg mL -1 DAP, 2 ± 0.04 µg mL -1 PH, 3 ± 0.1 µg mL -1
2,6DOL-PAP, 13 ± 0.2 µg mL -1 6OL-PAP and 24 ± 0.3
µg mL -1 6PA-3-PH.
III. Spectrofluorimetric Analysis
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(I) Fluorescence Spectral Characteristics of 2,6-Diaminopyridine and Phenol

Figure 5. Excitation and emission spectra of DAP (0.004 µg mL-1)
and PH (0.1 µg mL-1).

Reference solutions of DAP and PH exhibit strong

Table 3. Regression and statistical parameters for spectrofluorimetric analysis
Analyte
(λex/λem)

Regression data (n = 5)

Concentration range

RSD%

Sa

Sb

LOD
LOQ
(µg mL-1) (µg mL-1)

(µg mL-1)

a

b

r

DAP (325/390)

0.0004-0.006

1

113812

0.9999

1.3

1.7

460

0.0001

0.0003

PH (270/299)

0.01-0.15

5277

0.9997

1.2

1.9

33

0.003

0.008

-1.6

a, Intercept; b, slope; r, correlation coefficient; Sa, standard deviation of intercept; Sb, standard deviation of slope; RSD%, relative standard
deviation for five determinations; LOD, limit of detection; LOQ, limit of quantification.

Table 4. Specificity, precision and accuracy of the spectrofluorimetric method
Ratio

Nominal value (µg mL-1)

Found (µg mL -1)a ±SD

RSD%b

Er % c

Spectrofluorimetric determination of DAP
8:125 DAP/PH

0.0016

0.00162±0.00003

1.9

+1

4:125 DAP/PH

0.0016

0.00159±0.00004

2.5

-0.6

2:125 DAP/PH

0.0004

0.00035±0.00002

5.7

-12.5

Spectrofluorimetric determination of PH

a

8:125 DAP/PH

0.025

0.0255±0.0003

1.2

+2

5:125 DAP/PH

0.01

0.0097±0.0002

2.1

-3

4:125 DAP/PH

0.05

0.051±0.0006

1.2

+2

Mean ± standard deviation of five determinations.
Percent relative standard deviation.
c
Percent relative error.
b
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native f luorescence in the visible and U V regions,
respectively. Figure 5 displays the fluorescence spectra
of DAP (at λ ex/em = 325/390 nm in acidic ethanol) and PH
(at λ ex/em = 270/299 nm in aqueous acidic solution). The
parent drug, PAP, has no intrinsic fluorescence emission
in either media. Accordingly, spectrofluorimetric determination of DAP and PH, at trace levels in PAP drug
substance and tablets, based on the measurement of their
native fluorescence, was investigated.
The yellow f luorescence emission of DAP was
compared in different diluting solvents. Quenching in
fluorescence intensity was in the order: ethanol, 1,4-dioxane, dimethylformamide, methanol, acetonitrile, water and
Britton Robinson buffer, pH 9. Ethanol was thus chosen
as the most appropriate solvent. However, the f luorescence emission of PH is best measured in aqueous acidic
solution because of the significant sharing of the organic
solvents to the fluorescence emission in the UV region.
(II) Quantitative Aspects
Spectrofluorimetric measurements of standard solutions of DAP and PH were taken under the specified
concentration ranges and wavelengths. Data recorded in
Table 3 summarize the characteristics of the calibration
plots.
The repeatability of the fluorimetric measurements
was assessed in ter m of RSD%. The RSD% values
computed for data near the middle of calibration ranges
were typically < 2% (5 determinations), as shown in Table 3.
The limits of detection (LOD) and quantification
(LOQ) were calculated according to the formulas; 3 s.b -1
and 10 s.b -1, respectively (where s is the standard deviation of replicate blank readings), as shown in Table 3.
The specificity of the f luorimetric measurements
of DAP at 390 nm (λ ex = 325 nm, in ethanol) and PH at
299 nm (λ ex = 270 nm, in aqueous acidic solution) was
assessed through analysis of standard mixtures of DAP
and PH. Table 4 summarizes the precision (%RSD) and
accuracy (%Er) of data obtained from five measurements.
Phenol did not interfere with the selective determination
of DAP up to a ratio of 125:4, PH:DAP (working concentration level, 0.0016 µg mL -1). No interference was
observed from DAP with the selective measurement of PH
up to a ratio of 8:125, DAP:PH (working concentration
level, 0.025 µg mL -1). In the view of the data obtained, it
could be concluded that selective determination of DAP/
PH as impurity in PAP-test samples is possible.
(III) Applications
1. L e vels of 2,6 -Diaminopyridine and Phenol in
Phenazopyridine HCl
The recovery was determined by spiking PAP reference substance with either PH, or DAP standard solution
at three levels. Into a set of 10-mL volumetric f lasks,
were prepared, standard samples containing fixed 2.5 µg

mL -1 of PAP and variable concentrations of either PH
(0.010-1.0 µg mL -1) or DAP (0.0008-0.006 µg mL -1) and
the volume was made to 10 mL with distilled water or
ethanol, respectively. The average % recoveries were:
from 98 to 101% for PH at a level down to 0.4% and from
97 to 100% for DAP at a level down to 0.032%.
2. Detection of Related Impurities in Phenazopyridine
HCl Drug Substance and Tablets
The developed f luorimetric method was applied to
confirm the purity/stability of PAP-assay tablets solutions. Only DAP could be detected and quantified (Table
2) while PH level was lower than the limit of detection.

CONCLUSIONs
The ar ticle demonst rated the acid-deg radation
prof ile of PA P. The identit y of f ive products was
confirmed with MS, 1H-NMR, 13C-NMR and other criteria. The method can identify and characterize two additional degradation products, PH and 6PA-3-PH, which
have not been recognized by the reported micellar electrokinetic chromatographic method (10). Advantageously,
the developed HPLC method could be used to quantify
impurity level down to 0.005%.
The USP spectrophotometric method for assay of
PAP drug substance can not be assigned as purity index
because of significant overlapping of the absorbance
spectra of the three azo/hydrazo degradants and PAP, all
showing a maximum in the vicinity of 400 nm. Also, the
USP HPLC method for assay of PAP tablets can resolve
PAP peak from all other related degradation products/
impurity peaks. However the latter can not be separated
under the method conditions.
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